Disease Domain | Count |
---|---|
Neoplasms | 2 |
Endocrinology and Metabolic Disease | 1 |
Immune System Diseases | 1 |
Hemic and Lymphatic Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Monoclonal antibody | 2 |
Small molecule drug | 1 |
Target |
Mechanism FGF23 antagonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. EU [+3] |
First Approval Date19 Feb 2018 |
Target |
Mechanism A2aR antagonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. JP |
First Approval Date25 Mar 2013 |
Target |
Mechanism CCR4 antagonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. JP |
First Approval Date30 Mar 2012 |
Start Date09 Nov 2022 |
Sponsor / Collaborator |
Start Date24 Nov 2021 |
Sponsor / Collaborator |
Start Date01 Apr 2021 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Burosumab-TWZA ( FGF23 ) | Familial Hypophosphatemic Rickets More | Approved |
KHK-2455 ( IDO1 ) | Urogenital Neoplasms More | Phase 1 |
Mogamulizumab-KPKC ( CCR4 ) | Carcinoma More | Phase 1 |
KHK-2823 ( CD123 ) | Acute Myeloid Leukemia More | Discontinued |
Ecromeximab ( GD3 ) | Melanoma More | Discontinued |